Patel Engineering wins Rs 2,037 crore contracts for Dam and Hydro projects
Patel Engineering Limited (PEL), a Mumbai-based infrastructure company, has been declared as the Lowest Bidder (L1) for two significant projects in India, with a combined value of over ₹2,000 crore.
Kondhane Dam Project in Maharashtra
The City and Industrial Development Corporation (CIDCO) has selected Patel Engineering for a ₹1,318.89 crore contract for the construction of the Kondhane Dam and its allied works. The dam will be built using Roller Compacted Concrete (RCC) technology.
The project is located in Kondhane village, Karjat Taluka, Raigad district, Maharashtra, and is scheduled to be completed within 42 months. Project Scope: Construction of a dam with a length of 1,209 meters and a height of 83 meters.
Associated civil works.
Hydro-mechanical and electrical works, including installation of three radial gates.
Electrical and manual gate control systems.
Other required electrification works.
HEO Hydro Electric Project in Arunachal Pradesh
In another development, the North Eastern Electric Power Corporation (NEEPCO) has declared Patel Engineering as L1 for a ₹718 crore contract (including taxes) for the 240 MW HEO Hydro Electric Project in Arunachal Pradesh. The project aims to generate 1,000 million units (MU) of electricity annually, contributing to regional power supply and national grid stability.
The project is located in Shi Yomi district, Arunachal Pradesh, with a scheduled completion timeline of 44 months. Project Scope: Civil and associated infrastructure construction.
Testing and commissioning of hydro-mechanical plant and machinery.
Successful operation and performance of all generating units of the 240 MW hydroelectric facility.
Patel Engineering's selection for these projects adds to its portfolio of large-scale infrastructure development contracts across the country.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
an hour ago
- Boston Globe
Will Trump's policies kill Massachusetts' life sciences leadership?
Advertisement Although the industry is centered in eastern Massachusetts, there's a statewide benefit from all the tax dollars those businesses and workers pay. Get The Gavel A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr. Enter Email Sign Up In all, Massachusetts organizations — including universities, research institutes, and hospitals — received $3.5 billion in funding from the National Institutes of Health. Massachusetts-headquartered companies raised $3.26 billion in venture capital funding. Among all drugs in the development pipeline in the United States, 15 percent were being made by companies headquartered in Massachusetts. But actions taken by President Trump and his administration — cutting funding for scientific research and universities, flirting with tariffs, fanning skepticism about vaccines — threaten to devastate the ecosystem. Today, the industry is at a precipice, and uncertainty abounds. Some companies are already feeling the pinch of terminated federal grants, while others are anxious about what might come. Taken together, Trump's policies could force some companies and scientists to take their money, talents, and products overseas. Advertisement Christopher Locher, CEO of Lowell-based Versatope Therapeutics, which develops a platform to deliver vaccines and therapeutics, said he worries the Greater Boston life sciences ecosystem is 'being flushed down the toilet.' For example, Trump is Trump's funding cuts are already having a large impact on some local companies. Part of the problem is the Trump administration isn't only cutting funding, but it's picking which technologies to fund — in some cases apparently based on politics more than science. Take flu vaccines. The Trump administration recently announced a $500 million campaign to fund the development of a universal flu vaccine, which doesn't require annual updates, using technology being worked on But simultaneously, he cut funding for other work on a universal flu vaccine. Versatope Therapeutics got $14 million in NIH funding and spent five years developing a universal flu vaccine. It had approval from the US Food and Drug Administration to begin clinical trials when Trump terminated the contract's remaining $8 million, with the reason given being 'convenience,' Locher said. Trump also Advertisement Company executives say decisions by Trump officials to disinvest in vaccine-related technology — and concerns about whether government will approve new technology — means it's nearly impossible to find private investment funding to replace lost federal dollars. 'We're faced with bankruptcy in the very near future,' Locher said. Ironically, given Trump's stated commitment to bringing businesses back to the United States, one potential option Locher is eyeing is opening a subsidiary abroad. Conducting clinical trials would be cheaper in another country, whether in Europe, Australia, or China, Locher said, and some countries are offering financial incentives to American companies to relocate. Companies also face a potential workforce brain drain. There have been MassBio officials said China has less rigorous — but faster — safety and research protocols than the US. Australia allows a faster timeline for clinical trials. If regulatory approval of medicines is held up because the FDA is understaffed, companies may seek European regulatory approval instead. The loss of talent to foreign countries will be compounded if the pipeline of local university graduates dries up. One draw for life sciences companies to Boston/Cambridge is the presence of elite schools like Harvard and MIT, with their potential for faculty collaboration and skilled graduates. Advertisement Trump is trying to Chip Clark, CEO at Vibrant Biomedicines in Cambridge, said cuts to university research funding both 'shrink the pipeline of great ideas' that form the basis for many biotech startups and translate to fewer available scientists. Clark said the administration's policies 'seem like a deliberate attempt to try to cede scientific leadership to Europe and Japan and Korea and China. ... They will be delighted to capitalize on our talent, technology, and investment capital to make their robust biotech sectors grow and ultimately compete successfully against the US industry,' he said. Don Ingber, founding director of the Wyss Institute for Biologically Inspired Engineering at Harvard University, said he has postdocs with US visas applying for jobs in Europe, and others who were accepted to work at Harvard but are going elsewhere. 'The fact that places like Harvard and MIT and American universities are magnets for the best and brightest from around the world is what's driven our technology economy and certainly the Boston/Cambridge ecosystem,' Ingber said. 'With this uncertainty, I fear we'll lose a generation.' Ingber, who was forced to stop work on two government-funded projects on drugs designed to prevent injury from radiation exposure, compared administration policies to 'eating seed corn' needed to grow crops. Advertisement Trump's vendetta will undermine one of the most vibrant state economies in the country and set back American science by years. And it's not just eastern Massachusetts that will pay a price; the entire country will. As Ingber noted, it might take years to see the impact of medicines or technologies that aren't developed because of these shortsighted cuts. Editorials represent the views of the Boston Globe Editorial Board. Follow us
Business Insider
an hour ago
- Business Insider
I'm a Gen Zer who landed a 6-figure job at Morgan Stanley before graduation. Here's what the process was like — and why you should refresh a surprisingly important part of your résumé.
This as-told-to essay is based on a conversation with Sara Thomas, 22, a 2025 graduate from the University of Chicago and incoming investment banking analyst at Morgan Stanley. Business Insider's recent " Path to Wall Street" series highlighted how finance careers continue to attract young talent, despite the industry's long hours and demanding entry-level roles. Entry-level bankers typically earn about $110,000 a year, not including bonuses. This interview has been edited for length and clarity. I had barely decided on banking as a career choice when I had to start preparing for interviews. My experience was similar to most stories I've heard about the banking world: the recruiting process starts early. Before submitting my internship applications, I spoke to about five people at each major bank — mostly recent UChicago grads and people the university's career advancement program connected me with — so they would recognize my name when they saw my résumé. Cold LinkedIn messaging didn't work very well for me. Those introductions are often necessary to get an interview. At most banks, I interviewed for multiple rounds, including calls focused on my personality and technical skills and a two-hour " super day." The whole process lasted about two weeks. Then, by the spring of my sophomore year, I was done. I landed an internship at Morgan Stanley, and I knew my full-time job would be set as long as I got a return offer. My prior internships had been at Bain Capital and the Chicago-based firm Ariel Investments. The only other career trajectory I considered in college was academia. I studied economics and considered getting involved with economics research, but I realized it wasn't for me. I just work better in a faster-paced finance environment. In my free time at school, I tried to focus on clubs and internships that would keep me close to startups and entrepreneurship, so I joined a venture capital fund on campus. I was also involved in a campus group for women and minorities interested in finance and investing. Those opportunities really helped me build my industry chops. I would tell any college student hoping to land a Wall Street or Silicon Valley job: be decisive. Even if investment banking or consulting isn't your lifelong passion, plan to commit to a career path sooner rather than later, so that you can give yourself the most amount of time to prepare, network, and do really well in the interviews. And, for the application process, students need to be careful with what they put on their résumé — recruiters pay a lot of attention to the "skills and interests" section at the bottom. Don't say that you're a mountain climber if you have never climbed a mountain, because people will ask you about your hobbies, and you need to be able to genuinely talk about them. Of course, your credentials matter, but I've found that recruiters are most interested in meeting well-rounded people. Job applications and postgrad life make me anxious sometimes. I've leaned on my friends a lot: Some aren't going into finance, others have gone through recruiting alongside me. I'm also grateful for my family — my Morgan Stanley role will be in San Francisco, and it will be the first time I've moved far from home, since I grew up in Chicago. Exercise has always been a coping strategy for me, too. I'm trying to build healthy habits and make sure I don't isolate myself. Those are the main ways I'm dealing with stress. Long, long term, my biggest goal is to be able to work for myself in some way. That could mean working at a big company that gives me a lot of autonomy to make decisions or starting my own company, if I am brave enough to do that. For now, I'm excited to keep building my career and learning from my coworkers. Having engaging conversations with people you've never met can be the most challenging part of the finance industry, but it's also the most rewarding.
Business Upturn
2 hours ago
- Business Upturn
NHPC declares COD for 3rd phase of Karnisar Solar Power Project in Bikaner
NHPC Limited has announced the commencement of commercial operations for the third phase of its 300 MW Karnisar Solar Power Project in Bikaner, Rajasthan. Following the successful completion of the trial run on June 5, 2025, the company declared the Commercial Operation Date (COD) for the third phase—adding 53.57 MW of capacity—effective June 7, 2025. With this milestone, the total commercially operational capacity of the Karnisar Solar Power Project now stands at 160.71 MW out of the planned 300 MW. This phased commissioning highlights NHPC's continued commitment to expanding its renewable energy portfolio and supporting India's clean energy transition. The project is a part of NHPC's broader strategy to diversify its energy mix beyond hydropower and contribute significantly to the nation's solar capacity. It aligns with India's ambitious renewable energy goals and showcases NHPC's growing presence in the solar sector. NHPC Q4 Results NHPC has reported a strong 52% year-on-year (YoY) jump in its consolidated net profit to ₹919.63 crore for the fourth quarter ended March 2025, compared to ₹605 crore in the same quarter last year. According to the company's regulatory filing, the impressive performance was primarily driven by a rise in total income, which grew to ₹2,672.11 crore in Q4 FY25 from ₹2,320.18 crore in Q4 FY24. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
